PE20070425A1 - Composicion farmaceutica que comprende acido 1-[4-(2-azepan-1-il-etoxi)-bencil]-2-(4-hidroxifenil)-3-metil-1h-indol-5-ol acetico (acetato de bazedoxifeno) como modulador selectivo del receptor de estrogenos - Google Patents
Composicion farmaceutica que comprende acido 1-[4-(2-azepan-1-il-etoxi)-bencil]-2-(4-hidroxifenil)-3-metil-1h-indol-5-ol acetico (acetato de bazedoxifeno) como modulador selectivo del receptor de estrogenosInfo
- Publication number
- PE20070425A1 PE20070425A1 PE2006001025A PE2006001025A PE20070425A1 PE 20070425 A1 PE20070425 A1 PE 20070425A1 PE 2006001025 A PE2006001025 A PE 2006001025A PE 2006001025 A PE2006001025 A PE 2006001025A PE 20070425 A1 PE20070425 A1 PE 20070425A1
- Authority
- PE
- Peru
- Prior art keywords
- acetate
- formulation
- weight
- amount
- bazedoxifeno
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) ACIDO 1-[4-(2-AZEPAN-1-IL-ETOXI)-BENCIL]-2-(4-HIDROXIFENIL)-3-METIL-1H-INDOL-5-OL ACETICO (ACETATO DE BAZEDOXIFENO) COMO UNA FORMA POLIMORFICA CRISTALINA QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,1% A 30% EN PESO DE LA FORMULACION; B) UN PRIMER RELLENO/ DILUYENTE TAL COMO AZUCARES, CELULOSA MICROCRISTALINA, ALMIDON, ENTRE OTROS, QUE SE ENCUENTRA EN UNA CANTIDAD DE 5% A 85% EN PESO DE LA FORMULACION; C) UN SEGUNDO RELLENO/ DILUYENTE TAL COMO LACTOSA QUE SE ENCUENTRA EN UNA CANTIDAD DE 5% A 85% EN PESO DE LA FORMULACION; D) UN ANTIOXIDANTE TAL COMO ACIDO ASCORBICO QUE SE ENCUENTRA EN UNA CANTIDAD DE HASTA 15% EN PESO DE LA FORMULACION; E) UN AGENTE DESLIZANTE/ DESINTEGRANTE TAL COMO GLICOLATO SODICO DE ALMIDON QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,01% A 10% EN PESO DE LA FORMULACION; F) UN LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,01% A 10% EN PESO DE LA FORMULACION. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DE LA COMPOSICION. EL ACETATO DE BAZEDOXIFENO ES UN MODULADOR SELECTIVO DEL RECEPTOR DE ESTROGENOS SIENDO UTIL EN EL TRATAMIENTO DE OSTEOPOROSIS POSTMENOPAUSICA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71076105P | 2005-08-24 | 2005-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070425A1 true PE20070425A1 (es) | 2007-07-02 |
Family
ID=37772333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006001025A PE20070425A1 (es) | 2005-08-24 | 2006-08-23 | Composicion farmaceutica que comprende acido 1-[4-(2-azepan-1-il-etoxi)-bencil]-2-(4-hidroxifenil)-3-metil-1h-indol-5-ol acetico (acetato de bazedoxifeno) como modulador selectivo del receptor de estrogenos |
Country Status (21)
Country | Link |
---|---|
US (1) | US7771744B2 (es) |
EP (1) | EP1919456A2 (es) |
JP (2) | JP2009506053A (es) |
KR (2) | KR101584674B1 (es) |
CN (1) | CN101304731B (es) |
AR (1) | AR056471A1 (es) |
AU (1) | AU2006283121A1 (es) |
BR (1) | BRPI0615341A2 (es) |
CA (1) | CA2620174A1 (es) |
CR (1) | CR9746A (es) |
EC (1) | ECSP088214A (es) |
GT (1) | GT200600383A (es) |
IL (2) | IL189648A (es) |
MX (1) | MX2008002484A (es) |
NO (1) | NO20080991L (es) |
PE (1) | PE20070425A1 (es) |
RU (1) | RU2417084C2 (es) |
SV (1) | SV2008002825A (es) |
TW (1) | TW200738281A (es) |
WO (1) | WO2007024961A2 (es) |
ZA (1) | ZA200801742B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06011685A (es) * | 2004-04-08 | 2006-12-14 | Wyeth Corp | Formulaciones de dispersiones solidas de acetato de bazedoxifeno. |
AU2006283121A1 (en) * | 2005-08-24 | 2007-03-01 | Wyeth | Bazedoxifene acetate formulations and manufacturing process thereof |
AU2007232098A1 (en) * | 2006-03-31 | 2007-10-11 | Rubicon Research Private Limited | Directly compressible composite for orally disintegrating tablets |
WO2008079342A2 (en) * | 2006-12-21 | 2008-07-03 | Mallinckrodt Inc. | Composition of and method for preparing orally disintegrating tablets |
US20100016582A1 (en) * | 2008-02-11 | 2010-01-21 | Wyeth | Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate |
ITMI20091109A1 (it) | 2009-06-23 | 2010-12-24 | Wyeth Corp | Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione |
CA2818068C (en) * | 2010-11-30 | 2019-06-11 | Wista Laboratories Ltd. | Formulations comprising methylthioninium chloride |
EP2471770A1 (en) * | 2010-12-28 | 2012-07-04 | Sandoz Ag | Method of preparing polymorphic pure form A of bazedoxifene acetate |
WO2013182170A1 (en) | 2012-06-07 | 2013-12-12 | Zentiva, K. S. | Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate |
WO2013182169A1 (en) | 2012-06-07 | 2013-12-12 | Zentiva, K. S. | Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate |
CN103877581B (zh) * | 2014-03-24 | 2016-03-02 | 江苏知原药业有限公司 | 一种性能优异的乙酸巴多昔芬缓释制剂 |
WO2018182205A1 (ko) * | 2017-03-30 | 2018-10-04 | 한미약품 주식회사 | 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물 |
KR101940569B1 (ko) * | 2017-05-24 | 2019-01-21 | 아주대학교산학협력단 | 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 |
CN112076163B (zh) * | 2019-06-14 | 2023-06-20 | 四川科伦药物研究院有限公司 | 一种醋酸巴多昔芬片的药物组合物及其制备方法 |
CN111004165A (zh) * | 2019-12-03 | 2020-04-14 | 南京正济医药研究有限公司 | 一种醋酸巴多昔芬晶型a的制备方法 |
CN112754999A (zh) * | 2021-01-23 | 2021-05-07 | 郑州泰丰制药有限公司 | 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法 |
CN113368075A (zh) * | 2021-06-29 | 2021-09-10 | 郑州泰丰制药有限公司 | 一种醋酸巴多昔芬片及其制备方法 |
CA3229700A1 (en) * | 2021-08-23 | 2023-03-02 | Jan Brabek | Treatment of covid-19 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5686094A (en) * | 1991-04-01 | 1997-11-11 | Theratech, Inc. | Controlled release formulations for the treatment of xerostomia |
CN1119998C (zh) * | 1995-06-22 | 2003-09-03 | 阿克佐诺贝尔公司 | 去氧孕烯的压制干颗粒片 |
US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
CN1429222A (zh) | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | 激酶抑制剂 |
AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
CN1658868A (zh) * | 2002-06-13 | 2005-08-24 | 惠氏公司 | 巴泽昔芬治疗方案 |
RU2006123939A (ru) | 2004-01-13 | 2008-02-20 | Вайет (Us) | Лечение остеопороза, связанного с терапией ингибиторами ароматазы |
JP2007532548A (ja) | 2004-04-07 | 2007-11-15 | ワイス | バゼドキシフェンアセテートの結晶質多形体 |
SG151331A1 (en) | 2004-04-07 | 2009-04-30 | Wyeth Corp | Crystalline polymorph of a bazedoxifene acetate |
CN1938272A (zh) * | 2004-04-07 | 2007-03-28 | 惠氏公司 | 巴泽多昔芬醋酸盐的结晶多晶型物 |
MXPA06011685A (es) * | 2004-04-08 | 2006-12-14 | Wyeth Corp | Formulaciones de dispersiones solidas de acetato de bazedoxifeno. |
AU2006283121A1 (en) * | 2005-08-24 | 2007-03-01 | Wyeth | Bazedoxifene acetate formulations and manufacturing process thereof |
-
2006
- 2006-08-23 AU AU2006283121A patent/AU2006283121A1/en not_active Abandoned
- 2006-08-23 CA CA002620174A patent/CA2620174A1/en not_active Abandoned
- 2006-08-23 MX MX2008002484A patent/MX2008002484A/es active IP Right Grant
- 2006-08-23 JP JP2008528116A patent/JP2009506053A/ja not_active Withdrawn
- 2006-08-23 CN CN2006800394740A patent/CN101304731B/zh not_active Expired - Fee Related
- 2006-08-23 AR ARP060103666A patent/AR056471A1/es not_active Application Discontinuation
- 2006-08-23 KR KR1020087006992A patent/KR101584674B1/ko active IP Right Grant
- 2006-08-23 PE PE2006001025A patent/PE20070425A1/es not_active Application Discontinuation
- 2006-08-23 WO PCT/US2006/032935 patent/WO2007024961A2/en active Application Filing
- 2006-08-23 KR KR1020147017847A patent/KR20140088917A/ko not_active Application Discontinuation
- 2006-08-23 TW TW095130979A patent/TW200738281A/zh unknown
- 2006-08-23 BR BRPI0615341-0A patent/BRPI0615341A2/pt not_active Application Discontinuation
- 2006-08-23 RU RU2008107580/15A patent/RU2417084C2/ru active
- 2006-08-23 GT GT200600383A patent/GT200600383A/es unknown
- 2006-08-23 US US11/508,801 patent/US7771744B2/en active Active
- 2006-08-23 EP EP06802170A patent/EP1919456A2/en not_active Withdrawn
-
2008
- 2008-02-19 CR CR9746A patent/CR9746A/es not_active Application Discontinuation
- 2008-02-21 IL IL189648A patent/IL189648A/en active IP Right Grant
- 2008-02-22 EC EC2008008214A patent/ECSP088214A/es unknown
- 2008-02-22 SV SV2008002825A patent/SV2008002825A/es not_active Application Discontinuation
- 2008-02-22 ZA ZA200801742A patent/ZA200801742B/xx unknown
- 2008-02-27 NO NO20080991A patent/NO20080991L/no not_active Application Discontinuation
-
2013
- 2013-06-11 JP JP2013122658A patent/JP2013209419A/ja active Pending
-
2014
- 2014-06-26 IL IL233392A patent/IL233392A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
MX2008002484A (es) | 2008-04-07 |
IL189648A0 (en) | 2008-08-07 |
KR20080043853A (ko) | 2008-05-19 |
IL189648A (en) | 2014-07-31 |
JP2009506053A (ja) | 2009-02-12 |
US20070048374A1 (en) | 2007-03-01 |
AU2006283121A1 (en) | 2007-03-01 |
WO2007024961A2 (en) | 2007-03-01 |
US7771744B2 (en) | 2010-08-10 |
NO20080991L (no) | 2008-05-15 |
JP2013209419A (ja) | 2013-10-10 |
CN101304731A (zh) | 2008-11-12 |
CA2620174A1 (en) | 2007-03-01 |
GT200600383A (es) | 2007-03-29 |
TW200738281A (en) | 2007-10-16 |
KR20140088917A (ko) | 2014-07-11 |
BRPI0615341A2 (pt) | 2011-05-17 |
ZA200801742B (en) | 2010-10-27 |
CN101304731B (zh) | 2012-06-20 |
SV2008002825A (es) | 2008-06-30 |
EP1919456A2 (en) | 2008-05-14 |
CR9746A (es) | 2008-08-21 |
AR056471A1 (es) | 2007-10-10 |
KR101584674B1 (ko) | 2016-01-13 |
IL233392A (en) | 2017-02-28 |
WO2007024961A3 (en) | 2007-06-28 |
IL233392A0 (en) | 2014-08-31 |
RU2008107580A (ru) | 2009-09-27 |
RU2417084C2 (ru) | 2011-04-27 |
ECSP088214A (es) | 2008-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20070425A1 (es) | Composicion farmaceutica que comprende acido 1-[4-(2-azepan-1-il-etoxi)-bencil]-2-(4-hidroxifenil)-3-metil-1h-indol-5-ol acetico (acetato de bazedoxifeno) como modulador selectivo del receptor de estrogenos | |
PE20070691A1 (es) | Formulacion de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin-2(s)-carbonitrilo de liberacion modificada | |
ES2526555T3 (es) | Composición fungicida y método para controlar enfermedades de plantas | |
PE20130227A1 (es) | Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt | |
CL2008000133A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e | |
NZ600207A (en) | Substituted 4-aminocyclohexane derivatives | |
PE20080362A1 (es) | Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
IL212351A (en) | Non-hygroscopic crystalline forms of (r) –5– [3– chloro – 4– (3,2 – dihydroxy – propoxy) –benz [z] yladen] –2 - ([z] - profileimino) –3– o– tolyl -Tiazolidine-4-On, containing between 0 and 0.5 equivalents of water to the equivalent molecule, pharmaceutical preparations and their uses | |
PE20120599A1 (es) | Metodo para producir material de sabor | |
PE20080117A1 (es) | Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol | |
PE20091014A1 (es) | Compuestos espiro y uso farmaceutico de los mismos | |
PE20100265A1 (es) | Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion | |
CL2011000394A1 (es) | Compuestos derivados de 1-hidroximetil-6,8-dioxa-biciclo[3.2.1]octano-2,3,4-triol, inhibidores de sglt2; cocristal que comprende a dicho compuesto y l-prolina o acido l-piroglutamico; composicion farmaceutica que los comprende; utiles para el tratamiento de la obesidad y diabetes de tipo 2. | |
ECSP088239A (es) | Composición de liberación de fármaco sostenida | |
PE20160874A1 (es) | Compuestos quimicos | |
MX2014001671A (es) | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-aluiniloxi-etil}-1h[1,2,4]triazol sustituidos. | |
ECSP10010160A (es) | Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep) | |
PE20080522A1 (es) | Derivados de indol como inhibidores de los transportadores de glucosa dependientes de sodio (sglt) | |
TW200612976A (en) | Peptidic vasopressin receptor agonists | |
EA201200968A1 (ru) | Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин | |
PL2004168T3 (pl) | Stabilna doustna kompozycja farmaceutyczna zawierająca agonistów receptorów hormonów tarczycy | |
NZ630488A (en) | Piperidine derivatives for gpr119 agonist | |
CL2007001597A1 (es) | Compuestos derivados de 2-oxo-piridin-1(2h)-il-tiazol, imidazol o tiofen-carboxamida; composicion farmaceutica; y uso para el tratamiento de una enfermedad mediada por la estearoil-coa-desaturasa, tal como sindrome metabolico, hipertension y diabetes | |
WO2008059370A8 (en) | Substituted bicyclocarboxyamide compounds | |
CO6270306A2 (es) | Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FX | Voluntary withdrawal |